Arrakis Therapeutics
This is an actual day job — I am Chairman and CEO. They pay me a salary and I hold shares. Arrakis is trying to unlock vast domains of previously-undruggable biology for therapeutic benefit with its proprietary platform for RNA-targeted small molecules (rSMs). Want to hear how (sort of)? Check out my recent blog post.
learn more
Obsidian Therapeutics
I used to be CEO of this fantastic company; now I’m merely an ornery Board member. That all means I’m a significant shareholder. But that’s not why I love this company. I love it because of its powerful technology platform and wonderful, talented people. Obsidian is using synthetic biology to build pharmacologic operating systems for living medicines. This team will build the next generation of living medicines.
learn more
Scholar Rock
I am on the Board of Directors and Scientific Advisory Board and receive a cash stipend and hold equity. Scholar Rock targets the intimate cell-to-cell signals that maintain homeostasis in complex tissues. Scholar Rock’s current focus is members of the TGFβ superfamily. Its lead program, SRK-015, is an antibody that blocks the activation of myostatin and is being tested in patients with spinal muscular atrophy.
learn more
Synlogic
I don’t know exactly what I am here, perhaps an advisor? But I do hold some equity and attend occasional meetings of advisors and founders. Synlogic is using synthetic biology to build novel probiotics to treat disease.
learn more
FutuRx
I am a paid member of the Scientific Advisory Board of this impressive Israeli biotech accelerator and incubator. FutuRx is funded by Johnson & Johnson Innovation — JJDC, Takeda Ventures, and Orbimed Israel Partners and further supported by the Israeli government.
learn more
Novartis Venture Fund
I am on the Board of Directors and receive a cash stipend for my service.
learn more
X4 Pharmaceuticals
I used to be on the Board of Directors of this company and still hold shares. But I’m no longer privy to any insider information. X4 is a clinical-stage company targeting the chemokine receptor CXCR4, a traffic cop for immune cells, to treat cancer and WHIM syndrome, a rare primary immunodeficiency arising from mutations in the CXCR4 gene.
learn more